|
| Search for Cases |
|
Case Details |
|
Case Code: LDEN136
|
| Case Length: 17 Pages |
| Period: 2018 |
| Pub Date: 2019 |
| Teaching Note: Available |
| Price: Rs.500 |
| Organization : Dr. Reddy’s Laboratories Ltd
|
| Industry :Pharmaceuticals |
| Countries : India; United States; Germany |
| Themes:
|
|
|
|
|
Dr. Reddy`s Laboratories: Challenges ahead for Erez Israeli |
|
|
|
|
| <<Previous Page |
INTRODUCTION |
| |
| On March 29, 2018, India-based multinational pharmaceutical company Dr Reddy’s Laboratories (DRL) announced a change in the Management Council. The Council had witnessed a churn of employees over the previous few years, with several retiring from the company or joining competitors. The company named Erez Israeli (Israeli) as the new Chief Operating officer (COO) and Global Head of Generics &Pharmaceutical Services & Active Ingredients (PSAI) following the retirement of COO Abhijit Mukherjee (Mukherjee) on March 31, 2018. Israeli would report to the Co-Chairman and Chief Executive Officer G.V. Prasad (Prasad)...
|
| |
 |
| or |
 |
| or |
PayPal (11 USD)
|
|
|
| |
|
| |
| BACKGROUND NOTE - Next Page>> |
| |
|
| |
|
|
|
